Drug­mak­ers with White House MFN deals claim ex­emp­tion from pro­posed Medicare pric­ing tests
Com­pa­nies that have vol­un­tar­i­ly agreed to drug pric­ing deals with the White House ap­pear to be ex­empt from two new CMS demon­stra­tion pro­grams that have …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
To in­dus­try’s dis­may, CMS presents two Medicare pay­ment demos as part of Trump's MFN plan
Chi­na's new com­mer­cial in­sur­ance mod­el could broad­en ac­cess to Alzheimer's drugs
US ac­cus­es six peo­ple in scheme to ma­nip­u­late Ole­ma On­col­o­gy's share price
Up­dat­ed: Pfiz­er dis­clos­es pa­tient death in Hym­pa­vzi he­mo­phil­ia tri­al
No­vo Nordisk eyes a strong launch with FDA ap­proval of obe­si­ty pill
Neu­ro­crine’s In­grez­za flunks piv­otal study in dys­k­i­net­ic cere­bral pal­sy
Gilead­'s her­pes deal; FDA ap­provals for Boehringer, Roche
The End­points win­ners and losers list: Who was up and who was down in 2025
Up­dat­ed: Bris­tol My­ers, J&J bring IRA fight to Supreme Court as 'regime of forced sales' is poised to take ef­fect